CLAIMS

What is claimed is:

1. A method of suspending the onset of type 1 diabetes in a subject that has undergone IAA seroconversion, the method comprising administering to the subject a pharmaceutically acceptable composition comprising at least one immunoglobulin selected from the group consisting of INS, GAD, an insulin protein, a peptide derived from insulin, a diabetogenic epitope, and a T cell receptor engaging determinant; wherein the composition is administered to the subject in one or more dosage administrations.

2. The method of claim 1, wherein the immunoglobulin is human or humanized.

3. The method of claim 1, wherein the subject is a human subject.

4. The method of claim 1, wherein the administration of the composition to the subject results in down regulation of an autoreactive T cell.

5. The method of claim 1, wherein a peptide is inserted within a variable region of the immunoglobulin.

6. The method of claim 5, wherein the variable region of the immunoglobulin comprises a CDR1, a CDR2, or a CDR3 region.

7. The method of claim 5, wherein activation of an autoreactive T cell specific for the peptide is substantially reduced or prevented.

8. The method of claim 1, wherein the INS comprises INSß.

9. The method of claim 8, wherein the INSß is soluble.

10. The method of claim 9, wherein the soluble INSß is capable of binding to at least one Fc receptor.

11. The method of claim 10, wherein the Fc receptor is a Fcγ receptor.

12. The method of claim 10, wherein the composition is endocytosed by antigen presenting cells.

13. The method of claim 1, wherein the GAD comprises GAD 1, GAD2, or GAD65.

14. The method of claim 1, wherein the subject is IAA-positive.

15. The method of claim 1, wherein the subject is GAD positive.

16. The method of claim 1, wherein the subject has not developed hyperglycemia.

17. The method of claim 1, wherein the subject expresses a type 1 diabetes predisposition marker.

18. The method of claim 1, wherein upon administration of the composition to the subject, the subject undergoes a dose dependent suspension, prevention, or delay in the onset of type 1 diabetes.

19. The method of claim 1, wherein the administration of the composition occurs before the type-1 diabetes progresses to an irreversible stage.

20. A composition for suppressing the onset of type 1 diabetes in a subject that has undergone IAA seroconversion, the composition comprises: a pharmaceutically acceptable composition comprising at least one immunoglobulin selected from the group consisting of INS, GAD, an insulin protein, a peptide derived from insulin, a diabetogenic epitope, and a T cell receptor engaging determinant.